The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Wiederschain, G. Y. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909090156 · Cited by 4,083
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 10×
“Stimulation of ECs with FGF2 or a combination of IL-10 and TGF-b1 led to reduction of SNA-reactive glyco-epitopes, as compared to resting, IL-17- or IFN-g-treated ECs (Figures 1B and 1C), suggesting that pro- or anti-inflammatory signals may either mask or unmask Gal1-specific binding sites.”
InfluentialGlycosylation in Cellular Mechanisms of Health and Disease
Ohtsubo, K., & Marth, J. D. (2006) · Cell · doi:10.1016/j.cell.2006.08.019 · Cited by 2,788
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., & Adams, R. H. (2009) · Cell · doi:10.1016/j.cell.2009.03.025 · Cited by 1,107
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., & Iruela-Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,046
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Toscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., Hernandez, J. D., Zwirner, N. W., Poirier, F., Riley, E. M., Baum, L. G., et al. (2007) · Nature Immunology · doi:10.1038/ni1482 · Cited by 653
Self-citationHart, G. W., & Copeland, R. J. (2010) · Cell · doi:10.1016/j.cell.2010.11.008 · Cited by 643
Suppression of tumor growth and metastasis in Mgat5-deficient mice
Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R., & Dennis, J. W. (2000) · Nature Medicine · doi:10.1038/73163 · Cited by 569
Rubinstein, N., Alvarez, M., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 531
Self-citationGalectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
Thijssen, V. L. J. L., Postel, R., Brandwijk, R. J. M. G. E., Dings, R. P. M., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603883103 · Cited by 497
Ilarregui, J. M., Croci, D. O., Bianco, G. A., Toscano, M. A., Salatino, M., Vermeulen, M. E., Geffner, J. R., & Rabinovich, G. A. (2009) · Nature Immunology · doi:10.1038/ni.1772 · Cited by 476
Self-citationMetabolism, Cell Surface Organization, and Disease
Dennis, J. W., Nabi, I. R., & Demetriou, M. (2009) · Cell · doi:10.1016/j.cell.2009.12.008 · Cited by 450
Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis
Nangia-Makker, P., Honjo, Y., Sarvis, R., Akahani, S., Hogan, V., Pienta, K. J., & Raz, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64959-0 · Cited by 446
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Starossom, S. C., Mascanfroni, I. D., Imitola, J., Cao, L., Raddassi, K., Hernandez, S. F., Bassil, R., Croci, D. O., Cerliani, J. P., Delacour, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.023 · Cited by 354
Self-citationRegulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer
Rabinovich, G. A., & Croci, D. O. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.004 · Cited by 338
Self-citationHGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
López-Lucendo, M. F., Solís, D., André, S., Hirabayashi, J., Kasai, K.-I., Kaltner, H., Gabius, H.-J., & Romero, A. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.078 · Cited by 295
Sacchettini, J. C., Baum, L. G., & Brewer, C. F. (2001) · Biochemistry · doi:10.1021/bi002544j · Cited by 293
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Méndez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2418 · Cited by 261
Self-citationGalectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege
Le, Q.-T., Shi, G., Cao, H., Nelson, D. W., Wang, Y., Chen, E. Y., Zhao, S., Kong, C., Richardson, D., O'Byrne, K. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0206 · Cited by 258
Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity
Thijssen, V. L., Barkan, B., Shoji, H., Aries, I. M., Mathieu, V., Deltour, L., Hackeng, T. M., Kiss, R., Kloog, Y., Poirier, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4150 · Cited by 244
Fu, J., Gerhardt, H., McDaniel, J. M., Xia, B., Liu, X., Ivanciu, L., Ny, A., Hermans, K., Silasi-Mansat, R., McGee, S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36077 · Cited by 242
Hsieh, S. H., Ying, N. W., Wu, M. H., Chiang, W. F., Hsu, C. L., Wong, T. Y., Jin, Y. T., Hong, T. M., & Chen, Y. L. (2008) · Oncogene · doi:10.1038/sj.onc.1211029 · Cited by 229
VEGF Receptor 2 Endocytic Trafficking Regulates Arterial Morphogenesis
Lanahan, A. A., Hermans, K., Claes, F., Kerley-Hamilton, J. S., Zhuang, Z. W., Giordano, F. J., Carmeliet, P., & Simons, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.02.016 · Cited by 228
Markowska, A. I., Jefferies, K. C., & Panjwani, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.226423 · Cited by 218
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215
Glycosylation Changes in Cancer
Varki, A. P., Kannagi, R., Toole, B. P., & Stanley, P. (2009) · doi:10.1101/glycobiology.3e.047 · Cited by 209
Barrionuevo, P., Beigier-Bompadre, M., Ilarregui, J. M., Toscano, M. A., Bianco, G. A., Isturiz, M. A., & Rabinovich, G. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.436 · Cited by 206
Self-citationInhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A., & Lawrence, T. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6389 · Cited by 201
Croci, D. O., Salatino, M., Rubinstein, N., Cerliani, J. P., Cavallin, L. E., Leung, H. J., Ouyang, J., Ilarregui, J. M., Toscano, M. A., Domaica, C. I., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111665 · Cited by 196
Self-citationLaderach, D. J., Gentilini, L. D., Giribaldi, L., Delgado, V. C., Nugnes, L., Croci, D. O., Al Nakouzi, N., Sacca, P., Casas, G., Mazza, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1260 · Cited by 170
Self-citationPlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 159
Self-citationTumor Galectin-1 Mediates Tumor Growth and Metastasis through Regulation of T-Cell Apoptosis
Banh, A., Zhang, J., Cao, H., Bouley, D. M., Kwok, S., Kong, C. S., Giaccia, A. J., Koong, A. C., & Le, Q. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4157 · Cited by 133
VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
D’Haene, N., Sauvage, S., Maris, C., Adanja, I., Mercier, M. L., Decaestecker, C., Baum, L., & Salmon, I. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067029 · Cited by 129
Heparan Sulfate Regulates VEGF165- and VEGF121-mediated Vascular Hyperpermeability
Xu, D., Fuster, M. M., Lawrence, R., & Esko, J. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177006 · Cited by 112
Kitazume, S., Imamaki, R., Ogawa, K., Komi, Y., Futakawa, S., Kojima, S., Hashimoto, Y., Marth, J. D., Paulson, J. C., & Taniguchi, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073106 · Cited by 107
Fernández, G. C., Ilarregui, J. M., Rubel, C. J., Toscano, M. A., Gomez, S. A., Bompadre, M. B., Isturiz, M. A., Rabinovich, G. A., & Palermo, M. S. (2004) · Glycobiology · doi:10.1093/glycob/cwi026 · Cited by 105
Self-citationSong, Y., Aglipay, J. A., Bernstein, J. D., Goswami, S., & Stanley, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2719 · Cited by 104
Saito, T., Miyoshi, E., Sasai, K., Nakano, N., Eguchi, H., Honke, K., & Taniguchi, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200521200 · Cited by 93
Ouyang, J., Juszczyński, P., Rodig, S. J., Green, M. R., O'Donnell, E., Currie, T., Armant, M. A., Takeyama, K., Monti, S., Rabinovich, G. A., et al. (2011) · Blood · doi:10.1182/blood-2010-11-320481 · Cited by 85
Self-citationGourlaouen, M., Welti, J. C., Vasudev, N. S., & Reynolds, A. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446401 · Cited by 75
García-Vallejo, J. J., van Dijk, W., Hof, B. V. H., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20458 · Cited by 74
Self-citationGalectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes
Mathieu, V., de Lassale, E. M., Toelen, J., Mohr, T. T., Bellahcène, A., Goietsenoven, G. V., Verschuere, T., Bouzin, C., Debyser, Z., Vleeschouwer, S. D., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.142 · Cited by 68
Yokoe, S., Takahashi, M., Asahi, M., Lee, S. H., Li, W., Osumi, D., Miyoshi, E., & Taniguchi, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3023 · Cited by 57
Dissociation of the carbohydrate-binding and splicing activities of galectin-1
Voss, P. G., Gray, R. M., Dickey, S. W., Wang, W., Park, J. W., Kasai, K.-I., Hirabayashi, J., Patterson, R. J., & Wang, J. L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.07.003 · Cited by 33
Willhauck‐Fleckenstein, M., Moehler, T. M., Merling, A., Pusunc, S., Goldschmidt, H., & Schwartz‐Albiez, R. (2010) · Angiogenesis · doi:10.1007/s10456-010-9162-4 · Cited by 26
Cited by
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Metadata
- Authors
- Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., Mesri, E. A., Junttila, M. R., Bais, C., Shipp, M. A., Salatino, M., & Rabinovich, G. A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 156
- Issue
- 4
- Pages
- 744-758
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2134443544
- Cited by
- 505
- References
- 56
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.